Executive Summary
The treatment landscape for myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangements (MLN-FGFR1) has long been characterized by poor prognosis and limited therapeutic options. Historically, these aggressive malignancies, often referred to as the 8p11 myeloproliferative syndrome, have shown resistance to conventional chemotherapy, leaving hematopoietic stem cell transplantation (HSCT) as the only potentially curative intervention. However, the FIGHT-203 trial, a phase 2 study recently published in NEJM Evidence, marks a significant shift. The study evaluated pemigatinib, a potent, selective oral inhibitor of FGFR1, 2, and 3, in patients with MLN-FGFR1. The results demonstrate remarkable efficacy, particularly in the chronic phase of the disease, where the complete response rate reached 96%. This article provides a comprehensive analysis of the study’s methodology, clinical findings, and safety profile, emphasizing its implications for clinical practice.
